Introduction
The Friend virus (FV) belongs to a class of tumor inducing agents traditionally known as the slowtransforming retroviruses. Two isolates of the virus have been characterized, both of which induce a rapid splenomegaly in susceptible adult mice following a single viral injection (Ben David and Bernstein, 1991b; Kabat, 1990) . Infection by FV-A is marked by anemia while FV-P induces polycythemia. Both FV-P and FV-A are complexes of two distinct viral species: the replication defective spleen focus forming virus (SFFV-A in the case of FV-A, SFFV-P in the case of FV-P) and the replication-component Friend Murine Leukemia Virus (F-MuLV). The helper virus (F-MuLV) alone also induces erythroleukemias, characterized by anemia and splenomegaly, when injected into newborn pups of susceptible mouse strains (Silver and Kozak, 1986) .
F-MuLV, like other slow-transforming retroviruses, does not contain any oncogenic sequences. Instead, it induces tumors with its ability to integrate randomly into the host genome, where it either activates or inactivates cellular genes. This phenomenon, known as retroviral insertional mutagenesis, has led to the identi®cation of a number of proto-oncogenes that are intimately involved in the regulation of normal cellular growth and dierentiation (Jonkers and Berns, 1996) . In F-MuLV induced-erythroleukemias, genes altered by insertional mutagenesis include, among others, the Ets related transcription factor Fli-1 (Ben- David et al., 1991a) , and the erythroid-megakaryocytic transcription factor NF-E2 p45 (Lu et al., 1994) . In addition, the genes for the tumor suppressor p53 (Hicks and Mowat, 1988; Howard et al., 1996b) and the growth factor erythropoietin (Epo) (Howard et al., 1996a) are also targeted for mutation in these erythroleukemias, although the latter is activated by mechanisms independent of insertional mutagenesis. Signi®cantly, a number of these genes have been found to be mutated in a variety of human cancers, illustrating the utility of Friend erythroleukemia as an appropriate tumor model to study the genetic factors involved in cancer and in normal cell growth.
Another convenient feature of this model is its well characterized multistep nature, whereby genetic mutations accumulate at speci®c stages of the disease (BenDavid and Bernstein, 1991b) . F-MuLV, when inoculated into newborn mice, causes severe anemia and massive splenomegaly that overcomes its host in approximately 2 months. These symptoms are the result of a massive increase in the proliferation of an oligoclonal proerythroblast population. At the molecular level, this is induced by insertional activation of the Fli-1 gene (Ben-David et al., 1991a; Howard et al., 1993) . Cells from these tumors are unable to grow in vitro, and die rapidly in culture in a manner characteristic of apoptosis. However, these cells are able to grow in vivo when injected into a syngeneic adult animal, and they form secondary spleen tumors about 4 ± 6 weeks after transplant. A number of these tumors give rise to Epo-dependent cell lines in culture. These cell lines all bear mutations or deletions in the p53 gene, giving rise to the hypothesis that the inactivation of p53 may be responsible for the immortalization of aected cells in culture (Howard et al., 1993) . These p53 de®cient Epo-dependent cell lines can also give rise to tertiary tumors when injected into adult animals. The resulting tumors are capable of growing in culture in an Epo-independent manner largely due to their inability to produce Epo. The autocrine production of Epo in these cell lines is often the result of genomic Epo rearrangements (Howard et al., 1996a) .
The high frequency of p53 loss in Friend cell lines prompted us and others to examine the function of this gene within the context of Friend erythroleukemia. The precise role of p53 loss in the progression of Friend erythroleukemia is not entirely clear. Injection of FV-P in mice expressing a dominant-negative p53 was found to accelerate the onset of erythroleukemias, suggesting that the absence of wild-type p53 protein provides an in vivo advantage for disease progression (Lavigueur and Bernstein, 1991) . Furthermore, introduction of wild-type p53 into p53 de®cient Friend erythroleukemia cells is not tolerated and results in the induction of apoptosis (Johnson et al., 1993; Ryan et al., 1993) . These studies suggest that wild-type p53 may be responsible for apoptosis observed in cultured primary erythroleukemias. In direct contrast to FV-P, the rate of F-MuLV induced erythroleukemias in both p53 transgenic and non-transgenic littermates are identical (Howard et al., 1996b) . It was demonstrated also that erythroleukemic cells induced by F-MuLV in normal mice and in p53 transgenic mice die in culture by an apoptotic mechanism that is independent of p53 (Howard et al., 1996b) . However, all erythroleukemic cell lines have p53 mutations and possess chromosomal abnormalities, suggesting that the loss of this tumor suppressor gene may accelerate the acquisition of additional mutations required for the survival of erythroleukemias in culture, perhaps through the generation of genomic instability.
To further understand the role of p53 loss in F-MuLV induced-erythroleukemias, we studied the induction and the progression of F-MuLV induced erythroleukemias in p53 knockout mice. In contrast to p53 transgenic mice, which retain their endogenous wild-type p53 alleles, p537/7 mice represent a more de®nitive model of p53 loss during tumorigenesis. This is evident in the observation that 100% of p53 knockout mice develop spontaneous tumors within 6 months of age (Donehower et al., 1992; Jacks et al., 1994; Purdie et al., 1994) . However, similar to p53+/7 mice, only 20% of p53 transgenic mice develop tumors within 17 months (Lavigueur et al., 1989) . The results of this study show that the rate of tumor development is signi®cantly accelerated in p53 de®cient BALB/c mice when compared to control p53+/+ mice. A few of the primary tumors derived from p53+/7 or p537/7 mice gave rise to established cell lines in culture. In addition, the acquisition of Epo-independent cell growth in one of these primary tumors was associated with rearrangement of the Epo gene. These results demonstrate that mutations that arise late during progression of F-MuLV induced erythroleukemias are accelerated by the absence or loss of p53 in vivo. Furthermore, the loss of p53 expression in all of the established cell lines is largely associated with the loss of the remaining wild type allele in cell lines derived from p53+/7 mice. These results suggest that p53 loss accelerates the acquisition of mutations that are critical for the immortalization of erythroleukemic cells in culture.
Results

Acceleration of in vivo disease progression in BALB/c mice lacking p53
The p53 knockout animals were generated in the C57BL/6 and 129/sv strains of mice that are not susceptible to F-MuLV induced-erythroleukemia (data not shown). In order to induce tumors in these mice, it was necessary to backcross the p53 null allele into the susceptible BALB/c strain. To achieve this goal, we crossed a male 129/sv mouse heterozygous for the p53 null allele with female BALB/c mice. Ospring from this mating were genotyped by PCR. A male heterozygote from this F 1 litter, which was now 50% BALB/c in genetic character, was then crossed again with BALB/c wild-type females to produce F 2 ospring that were 75% BALB/c. It was found that pups from these mice (hereafter referred to as F 2 mice) were susceptible to F-MuLV induced-erythroleukemias. At the same time that these mice were generated, p53 knockout BALB/c mice became available commercially (Jackson laboratories). A heterozygous breeding pair of these mice were obtained, and their pups infected with F-MuLV. Together, 54 F 2 mice and 58 BALB/c newborn mice from the mating of p53+/7 breeding pairs were injected at birth with F-MuLV. These mice were monitored for the presence of spleen tumors, and were sacri®ced when they became moribund (see Table  1 for a summary of this data). It was found that, in F 2 mice, the average length of time between viral injection and sacri®ce in wild-type (p53+/+), heterozygous (p53+/7), and knockout (p537/7) mice was 66, 64, and 58 days, respectively (Figure 1) . A statistical analysis of variance (a=0.05) comparing the spectrum of p53 genotypes revealed no signi®cant dierence in the time that mice succumb to the disease. In contrast, it was found that BALB/c-p53+/+ mice succumbed to the disease in an average of 68 days, while p53+/7 and p537/7 littermates took 56 and 46 days, respectively (Figure 1 ). An analysis of variance (a=0.05) indicated a strong statistical dierence in these populations. Paired t-test comparison of disease progression (a=0.17) between wild-type and knockout mice, and also between heterozygous and knockout mice indicated signi®cant dierences between these populations. In contrast, the spleen weight and hematocrit values for both F 2 and BALB/c mice do not dier statistically regardless of p53 genotype (Figure 2) . Thus, the progression of F-MuLV induced-erythroleukemia appears to be accelerated in BALB/c-p53 de®cient mice. This phenomenon appears to be in¯uenced by strain dependent genetic factors, as F 2 mice lacking p53 are not similarly aected.
Growth of erythroleukemic cells in culture is an indirect consequence of p53 loss Our previous studies had shown that mutations within p53, which are only detected in cell lines established from transplanted F-MuLV induced-tumors, is associated with the immortalization of erythroleukemic cells in culture (Howard et al., 1993) . To determine whether the absence of p53 is sucient to immortalize primary leukemic cells, we isolated cell suspensions from the enlarged spleens of infected mice and placed them in liquid culture. To establish cell lines, growth media was supplemented with 20% FBS alone, or further supplemented with Epo or SCF, or both Epo+SCF containing media. It was found that 12 of the 54 tumors from F 2 mice, and seven of 58 BALB/c Days to sacri®cing were recorded for mice injected with F-MuLV, along with measured spleen weight and hematocrit values (ND=not determined). Means and standard deviations for groups of data are indicated in bold tumors gave rise to permanent cell lines in culture (Table 2) . Interestingly, only eight out of 21 tumors induced in the p537/7 genotype, from both F 2 and BALB/c backgrounds, gave rise to established cell lines. In addition, KHB24 was the only cell line established from a p53+/+ genotyped tumor (Tables  1 and 2) . Interestingly, this cell line appears to have lost p53 expression (see below).
We next assessed whether the p53 genotype of the host in¯uenced the growth of erythroleukemic cells in culture. It was observed that 18 of 19 cell lines were derived from tumors induced in p537/7 or p53+/7 mice (Tables 1 and 2 ). This demonstrates that p53 de®ciencies are associated strongly with the immortalization of erythroleukemic cells in culture. Furthermore, Southern blot analysis demonstrated that, of the ten cell lines derived from p53+/7 animals, eight had lost their remaining wild-type allele. In one of these cell lines, KH14, the two rearranged bands were also detected in the primary tumor used to establish it (Figure 3) . In this tumor, the observed band corresponding to the wild-type p53 most likely originated from the stroma cells present in the tumor that is absent in the KH14 cell line. However, it is also possible that the KH14 tumor is composed of two dominant cell clones which are either p53+/7 or p537/7 due to loss of the second p53 allele by rearrangement. Thus, the p537/7 cells survived and gave rise to the KH14 cell line. This observation strongly suggests that the loss of the second allele in KH14 erythroleukemic cells had occurred in vivo and not during establishment of these cells in culture. In at least another ®ve cell lines derived from heterozygous mice (KH31, KHB18, KHB29, KHB42 and KHB44) it appears that the hybridized band representing the p53 null allele is approximately two times more intense in the cell line than in the corresponding tumor ( Figure  3 ). This suggests that the wild-type allele in the tumor was lost and that the null allele was duplicated during the process of in vitro immortalization. Thus, 16 of 19 cell lines were shown to have a p537/7 status, as eight of the cell lines were derived from p537/7 mice and another eight were established from p53+/7 mice and had lost their remaining wild type p53 allele. Northern analysis of total RNA and Western analysis of protein isolated from these cell lines con®rmed the loss of wild-type p53 expression in all 19 cell lines (Tables 1 and 2 ). Together, these results show that the loss of p53 plays an essential role in the immortalization of these tumor cells.
To determine the clonal relationship between primary tumors and their respective cell lines, patterns of proviral integration were determined in these samples. Of the six p537/7 derived cell lines examined, all were shown to be clonally unrelated to their original tumor cell population as evidenced by dierent patterns of proviral integration. A representative Southern blot of DNA from four of these tumor/ cell line pairs hybridized with a F-MuLV envelope speci®c probe is shown in Figure 4A . These results suggest that the growing cells in culture are derived from a small sub-population of the corresponding primary tumor. The DNA of this minority population is undetectable amidst the presence of dominating cell populations in the tumor. This indicates that the majority of the p537/7 tumor cells are unable to survive in vitro. In turn, this provides strong evidence that p53 is not the eector of apoptosis in these tumor cells, and that the loss of p53 is necessary, but not sucient for immortalization in tissue culture.
Epo-independent cell growth occurs at an accelerated rate in p53 de®cient cells Once primary tumors gave rise to established cell lines, their growth factor dependency was determined by culturing them in the absence of Epo and/or SCF. It was found that seven of 12 cell lines from F 2 tumors Figure 1 Tumor incidence of primary erythroleukemias induced in p53 de®cient mice. The tumor incidence was measured as the day the animals were moribund. The p53 status of mice was determined by PCR as described in Materials and methods
Figure 2
The hematocrit (HCV) and spleen tumor weight of p53+/+, p53+/7 and p537/7 mice infected at birth with FMuLV. The HCVs and spleen tumor weights were measured on the day the animals were moribund could grow independently of Epo and SCF (Table 2) . Thus, Epo-independent cell growth could be observed in cultured primary erythroleukemias derived from p53 de®cient mice. To determine the mechanism of Epoindependence in these cell lines, a number of analyses were performed. Conditioned medium harvested from these newly established Epo-independent cell lines was screened for Epo activity by testing their ability to support the growth of the Epo-dependent cell line, HB9.1ED (Howard et al., 1993) . It was found that conditioned medium from three of these seven Epoindependent cell lines (KH9, KH14, and KH16) were capable of supporting the growth of HB9.1ED (Figure ). To determine whether these cell lines express Epo, poly(A) + mRNA was extracted from these cell lines and hybridized with an Epo cDNA probe ( Figure 5B ). Two cell lines (KH9 and KH14) were con®rmed to express their Epo gene. Interestingly, KH16 did not express measurable levels of Epo mRNA, although its conditioned supernatant was capable of supporting the growth of HB9.1ED. Finally, Southern blot analysis of genomic DNA from the Epo-independent cell lines demonstrated that one of the Epo-independent cell lines, KH14, has a genomic rearrangement in the Epo gene ( Figure 5C ). The observation that erythroleukemic cells from p53 de®cient animals can grow independently of Epo upon primary culture provides evidence that the loss of wild-type p53 accelerates the rate of growth of these tumor cells by promoting mutations within genes, like Epo, that confer growth factor independence.
Cell lines from p53 de®cient mice express erythroid-speci®c genes
In order to verify whether the established cell lines are erythroid in nature, the expression of a number of lineage speci®c markers was determined using Northern blot analysis. Examination of eight representative F 2 tumor derived cell lines show moderate to high expression levels of the erythroid speci®c gene, a-globin (Figure 6 ). The remainder of the cell lines also expressed globin and morphologically resembled erythroid progenitor cells (data not shown). Analysis of NF-E2p45, a transcription factor whose expression is largely restricted to the erythroid/megakaryocytic cell lineages, shows that it is also expressed in all of these cell lines (Figure 6 ). Collectively, the expression of these two erythroid speci®c genes con®rms that the leukemias induced by F-MuLV in these mice are derived from an erythroid lineage. An intriguing observation was made when the F-MuLV inducedtumors and their derivative cell lines were examined for the expression of Fli-1. Previous studies had demonstrated that insertional activation of this Ets-related transcription factor is an early genetic event in FMuLV induced-erythroleukemias and that its constitutive expression is essential for the transformation of erythroid progenitor cells (Ben-David et al., 1991a; Howard et al., 1993) . Southern analysis showed that the majority of tumors (99 out of 112) in this study acquired rearrangements of the Fli-1 locus (data not shown). Additionally, the majority of established cell lines were shown, by Northern analysis, to express Fli-1 (Table 2) . However, four of the erythroleukemic cell lines derived from F 2 mice (KH9, KH11, KH14, and KH16) do not express measurable levels of Fli-1 mRNA ( Figure 6 ). None of these cell lines express the related Ets gene, Sfpi-1, which is activated by insertional mutagenesis in FV-A/P induced erythroleukemias (data not shown). Expression of evi-1, a myeloid speci®c transcription factor whose insertional activation is frequently detected in F-MuLV derived myeloid leukemias (Bartholomew and Ihle, 1991; Bordereaux et al., 1987) , was also not detected in these cell lines. Furthermore, rearrangements of the Pim-1 and c-Myc genes, previously reported in erythroleukemias induced by F-MuLV (Dreyfus et al., 1990) , were not found in these cell lines (data not shown). Analysis of the pattern of proviral integration in KH9, KH11, KH14 and KH16 shows that the derived cell lines are clonally related to their primary tumors ( Figure 4B ). Incidentally, these tumors are derived from p53+/7 mice, and have lost the expression of wild type p53 (Figure 3 and Tables 1  and 2 ). Thus, a novel gene may be responsible for the transformation of these Fli-1 negative tumors that most likely serves an equivalent function to that of Fli-1. 
Discussion
Analysis of the molecular events responsible for FMuLV induced-erythroleukemias has identi®ed mutations in a number of genes, including Fli-1, p53, NF-E2 p45 and Epo. Of these mutations, insertional activation of Fli-1 appears to play a pivotal role in the initiation of erythroid transformation. While p53 mutations are only detected in immortalized erythroleukemic cells adapted to grow in culture, the exact role of this tumor suppressor gene during the in vivo progression of FMuLV induced-leukemias has not been fully established. In this study, we examined the progression of the F-MuLV induced erythroleukemias in mice lacking one or both alleles of p53. We provide evidence that the loss of p53 is required but not sucient for immortalization. The role of p53 in this process may stem from its ability, when lost or mutated, to accelerate the acquisition of growth/anti-apoptotic promoting mutations.
Analysis of the erythroleukemias induced by FMuLV in BALB/c mice has indicated that the rate of tumor development is signi®cantly accelerated in the p53 knockout background when compared with wildtype littermates. In contrast, F 2 mice that possess a mixed strain background (BALB/c and 129/sv) develop erythroleukemias at an equal rate regardless of their p53 genotype. This observation is consistent with previous reports that the genetic background of various mouse strains can alter the rate and the spectrum of tumors developed in p53-de®cient mice (Donehower et al., 1995b; Harvey et al., 1993) . These results may suggest that genetic factors in the BALB/c strain are able to complement the loss of p53 and Fli-1 activation to accelerate the in vivo progression of erythroleukemias induced by F-MuLV. Additionally, it is also possible that erythroid precursors in BALB/c mice are in a more proliferative state than those in F 2 mice. This would make the cells more susceptible to viral infection and would subsequently accelerate the probability of Fli-1 insertional activation, an event which provides the impetus for cellular proliferation in aected erythroid progenitor cells.
A direct association between p53 mutation and in vitro immortalization has been reported by us in FMuLV induced erythroleukemias (Howard et al., 1993) . Therefore, it is not surprising that F-MuLV induced tumors derived from p53 de®cient mice are more capable of adapting to growth in culture. However, it is clear that the lack of p53 expression is not sucient for the immortalization of these cells. This was made evident by the result that the majority of p537/7 tumor cells did not survive in culture, even when supplemented with exogenous growth factors. While one of the primary functions of p53 is the induction of apoptosis (Yonish-Rouach et al., 1991), our previous observation had shown that, in F-MuLV induced erythroleukemias, survival in culture is not due to the loss of p53-mediated apoptosis (Howard et al., 1996b) . Therefore, the ability to establish immortal erythroleukemic cell lines from F-MuLV inducedtumors may require additional mutations other than the activation of Fli-1 and the inactivation of p53. This is dramatically exempli®ed by our clonal analysis of p537/7 derived tumors and their derivative cell lines (Figure 4) . All of the cell lines examined were shown to be clonally unrelated to their respective tumor, suggesting that the vast majority of p537/7 tumor cells are unable to grow in culture and that other mutational events are required within minor subpopulations in vivo.
Interestingly, eight out of ten cell lines derived from the p53+/7 mice were shown by Southern analysis to have lost their remaining wild-type allele. This loss of heterozygosity (LOH) appears to be strongly favored during the immortalization of the tumor cells. A similar pattern of LOH within the p53 gene has been described for numerous human cancers and animal tumor models (Donehower et al., 1992; Jacks et al., 1994; Purdie et al., 1994) . For example, the loss of both p53 alleles has been demonstrated in human T-cell leukemias that have been immortalized in vitro (Cheng and Haas, 1990) . Additional studies in human colorectal tumors (Baker et al., 1990) and in ovarian cancers (Okamoto et al., 1991) also show that p53 mutations are often followed by the loss of the remaining wildtype allele.
There are few studies that delineate how LOH at the p53 locus occurs, although a number of mechanisms have been suggested. These include allelic deletions (Baker et al., 1990) , where the structure of the chromosome carrying the remaining wild-type allele is altered, and double mutations (Cheng and Haas, 1990; Ushijima et al., 1995) , where the remaining allele undergoes a second inactivating mutation. The results described in this study suggest an alternative mechanism: namely, the endoreplication of the mutant allele. Southern blot analysis of a signi®cant number of cell lines derived from p53+/7 erythroleukemias showed the sole presence of an ampli®ed p53 knockout allele, suggesting the duplication of this allele. The apparent conversion of the wild-type allele to a p53 null allele may have resulted from some type of error in mitotic segregation, such that one daughter cell received both copies of the p53 knockout-bearing chromatid. This daughter cell, now being p537/7, would then have been selected out during establishment in tissue culture. Alternatively, this scenario may have arisen from selective homologous recombination between wildtype and knockout alleles in tumor cells. Indeed, in embryonic stem cells heterozygous for neomycin resistance, conversion to homozygous resistant cells Figure 6 Expression of erythroid genes in erythroleukemia cell lines. Total RNA (20 mg) was denatured in formaldehyde, electrophoresed in 1% agarose, blotted onto nylon, and hybridized successively with the Fli-1, NF-E2 p45 and a-globin cDNA probes. RNA from HB9.2F-EI cells were used as control. The same blot was then hybridized with the tubulin probe for control loading can take place during growth in high concentrations of neomycin (Mortensen et al., 1992) . Additionally, we are not excluding the possibility that the rate of homologous recombination may be accelerated in p53+/7 tumor cells. This is consistent with the ability of wild-type p53 to maintain ®delity control by suppressing homologous recombination in cells (Dudenhoer et al., 1998) .
The strong selection for p53 mutations raises an important question: how does the loss of this tumor suppressor gene contribute to the immortalization process? The results of our previous studies exclude the possibility that the loss of p53 blocks apoptosis (Howard et al., 1996b) . Moreover, the viability of p537/7 mice and the lack of spontaneous erythroleukemias strongly argue against a possible role for p53 during erythroid dierentiation. However, the evidence presented here suggests that the loss of p53 promotes the rapid accumulation of mutations that subsequently confer immortality. The loss of cell cycle check points and the generation of genomic instability is a hallmark of tumor progression that is often associated with p53 mutation (Blount et al., 1993; Donehower et al., 1995a; Kuerbitz et al., 1992; Livingstone et al., 1992; Yin et al., 1992) . Moreover, change in chromosomal ploidy and gene ampli®cation has frequently been detected in cells from various organs of 4 ± 6-week old p537/7 mice (Fukasawa et al., 1997) . These phenomenon may also occur with the loss of this tumor suppressor gene in F-MuLV induced-erythroleukemias. For example, rearrangements of the Epo gene, independent of retroviral insertional mutagenesis, are frequently detected in F-MuLV induced-erythroleukemias and are associated with advanced tumorigenicity (Howard et al., 1996a) . In the present study, the acquisition of Epo independence in cell lines derived from p53 de®cient tumors is associated with the activation of the Epo gene that, in at least one case, involves genomic rearrangement. This is in accord with our previous observation that chromosomal abnormalities, also indicative of genomic instability, occur in erythroleukemic cell lines with p53 mutations (Howard et al., 1996b) .
Interestingly, the ability to establish cell lines directly from p53 de®cient tumor bearing mice directly contrasts with our lack of success to induce immortal cell lines from tumors of transgenic mice expressing dominant negative p53 (Howard et al., 1996b) . This may largely be explained by the degree of penetrance of p53 mutations in these two animal models. Knockout p53 mice develop tumors at an incidence rate of 100% by 6 months of age (Donehower et al., 1992; Jacks et al., 1994; Purdie et al., 1994) . In contrast, about 20% of transgenic mice expressing a dominant-negative mutant of p53 develop tumors within 17 months (Lavigueur et al., 1989) . Additionally, it has been demonstrated that mutant p53 is often not entirely dominant over wild-type p53 in certain cell types (Williams et al., 1995) . It seems, then, that the eects of p53 loss are more overt in the p537/7 knockout model than in mutant p53 transgenic mice. For this reason, it may have been easier to establish cell lines from the p53 knockout animals. Regardless, it appears in both models that the role of p53 loss is the same, and that other mutations are required in addition to the loss of p53 expression in order to immortalize Fli-1 expressing erythroleukemic cells.
Although the majority of F-MuLV induced-tumors acquire an insertionally activated Fli-1 gene, a number of the cell lines established in this study (KH9, KH11, KH14, and KH16) were shown not to express Fli-1. Analysis of other oncogenes documented in related erythroleukemias and myeloid leukemias, including Sfpi-1, Evi-1, c-Myc, and Pim-1, shows them not to be involved (Bartholomew and Ihle, 1991; Bordereaux et al., 1987; Dreyfus et al., 1990; Moreau-Gachelin et al., 1988) . In addition, it is unlikely that these erythroleukemias occurred spontaneously since these types of tumors have not been demonstrated in p537/7 mice (Donehower et al., 1992; Jacks et al., 1994; Purdie et al., 1994) . Given these results, it is likely that insertional activation or inactivation of a novel factor(s), not previously described for erythroleukemias, may be responsible for the transformation of this subset of erythroleukemias. Thus, isolation of this gene(s) could provide additional insight into the molecular mechanism of erythroid transformation.
In summary, the results of this study show that the loss of p53 accelerates the genetic events involved in the progression of erythroleukemias induced by FMuLV. The loss of p53 expression is critical for the immortalization of erythroleukemic cells in culture, although it is not directly responsible for this process. However, the absence of p53 appears to accelerate the acquisition of mutational events that confers a growth advantage to the transformed erythroblasts.
Materials and methods
Breeding and F-MuLV inoculation of newborn mice p53 heterozygous (+/7) males of the 129/sv strain (Jackson Laboratory) were mated with female p53+/+ BALB/c mice (Charles River Laboratories). F 1 ospring were p53 genotyped by PCR ampli®cation of tail DNA as described previously (Jacks et al., 1994) . p53+/7 F 1 mice were then mated with BALB/c females, and ospring were similarly genotyped. F 2 ospring were tested for sensitivity to FMuLV (clone 57) by a single intraperitoneal injection at birth (Shibuya and Mak, 1983) . It was found that these mice were susceptible to F-MuLV induced-erythroleukemia. Accordingly, two breeding pairs of p53+/7 F 2 mice were used to provide ospring for the experiments. Similarly, ospring from breeding pairs of BALB/c p53+/7 mice (obtained from Jackson Laboratory) were infected with FMuLV.
Induction of tumors in animals and establishment of cell lines
Newborn pups were injected intraperitoneally with F-MuLV clone 57 as described (Shibuya and Mak, 1983) . They were monitored for (1) enlarged abdomens causing hunched postures, a symptom of splenomegaly, and (2) a lack of movement re¯ecting low energy due to severe anemia, and were sacri®ced when moribund. Mice displaying these marked symptoms rarely survive for over a day. Blood samples were collected in capillary tubes for hematocrit measurements and tail tissues for PCR genotyping. Spleen tissue was homogenized in PBS, and cells in suspension were cultured in a-MEM media supplemented with 20% heat inactivated fetal bovine serum (Gibco ± BRL). Cells were cultured in this media alone, or with either 10% EPO, 10% SCF, or 10% of both growth factors. Epo was collected by ®ltering the supernatant from 2 day cultures of the Epoproducing cell line, HB9.2F (Howard et al., 1996a) . Similarly, stem cell factor (SCF) was harvested from the SCF-producing cells, BHK-MKL (provided by Dr S Tsai (Tsai et al., 1994) ). These conditions were maintained until cells began growing in culture, at which time FBS was reduced to 10% and growth factors were removed in order to determine the growth factor dependence of the cell lines. The average time for the establishment of the cell lines was about 2 ± 4 weeks and the growing cells were immediately used for DNA and RNA analysis.
Epo growth curve assays
Supernatant was ®ltered from 2 day cultures of the KH4, KH5, KH9, KH10, KH11, KH14, and KH16 Epoindependent cell lines. The Epo-dependent cell line, HB9.1ED (Howard et al., 1993) was then plated in 6-well dishes at a concentration of 5.5610 4 cells/ml in a-MEM media supplemented with 10% FBS and 25% of the ®ltered supernatant. Viable cells were counted by Trypan blue dye exclusion on days 2 and 4 of culture. The negative control consisted of HB9.1ED cells grown in a-MEM media with 10% FBS alone while the positive control included addition of 25% harvested supernatant from the known Epoproducing cell line HB9.2F-EI (Howard et al., 1996a) .
DNA isolation and Southern analysis
High molecular weight DNA was isolated from homogenized spleen tissue, tail samples, or cell lines as previously described (Howard et al., 1993) . Fifteen micrograms of genomic DNA from tumors or cell lines was digested overnight with appropriate restriction enzymes, and separated on 1% agarose gels. DNA was acid depurinated in 0.1 M HCl for 15 min before denaturation and capillary transfer onto nylon membranes using 106SSC. The membranes were hybridized with 100 ng of random primed DNA probe in 50% formamide, 56SSPE (206SSPE=3 M NaCl, 200 mM NaH 2 PO 4 .H 2 O, 20 mM EDTA), 16Denhardt's solution (0.02% bovine serum albumin, 0.02% Ficoll, 0.02% polyvinylpyrolidone), and 5% dextran sulfate at 428C. The ®lters were washed for 15 min twice at room temperature in 26SSC, 0.5% SDS, and then twice at 658C in 0.26SSC, 0.1% SDS.
RNA isolation and Northern analysis
Total cellular RNA was isolated from spleen, liver, kidney tissues, and from cell lines using TRIzol reagent (Gibco BRL) as instructed by the manufacturer. For the Epo expression analysis, the RNA was enriched for polyA + mRNA as described (Ben-David et al., 1992) . Twenty micrograms of total RNA or 5 ug of polyA + mRNA was dissolved in 2.2 M formaldehyde, incubated at 558for 15 min, and separated in a 1% agarose gel containing 0.66 M formaldehyde. Gels were washed twice in transfer buer (106SSC) for 20 min and capillary transferred overnight onto nylon. Membranes were then hybridized to probes as described above.
DNA probes
The p53 probe is a 0.9 kb BglII ± PstI cDNA fragment from mouse clone 27.1a (Jenkins et al., 1984) . The F-MuLV env probe is a 0.8 kb BamHI segment of plasmid pHC6 (Chow et al., 1987) . The probe used for the Epo analyses, MsPst1.0, is a 1.0 kb PstI genomic fragment of the murine Epo gene (McDonald et al., 1987) . The Fli-1 cDNA probe is a 1.7 kb EcoRI fragment of the BB4 plasmid (Ben-David et al., 1991a) . The a-globin probe is a 2.2 kb EcoRI fragment from plasmid PB1. The NF-E2 p45 probe is a 1.5 kb EcoRI cDNA fragment derived from the CB7 erythroleukemic cell line (Lu et al., 1994) . The Spi-1 probe is a BamHI fragment of plasmid unpublished) . The evi-1 probe is a 1.0 kb HindIII ± PstI fragment of plasmid pUC1.0HP (Mucenski et al., 1988) . The Pim-1 probe is a 1.2 kb BglII digest of plasmid CS-41 (Saris et al., 1991) and the c-Myc probe is a 2.6 kb XbaI ± HindIII fragment (Selten et al., 1984) , both of which were kindly supplied by Dr A Berns.
